BiotechTube
Visible Genomics

Visible Genomics

Cambridge, United States· Est.
visiblegenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Visible Genomics is a commercial-stage diagnostics company specializing in genetic risk assessment for Age-Related Macular Degeneration (AMD). Its core offerings are the AMDiGuard Risk Test for general population screening and the AMDiGuard Progression Test for patients with early-stage disease, both delivered as physician-ordered DTC kits. The company targets the large and growing AMD patient population by empowering optometrists and ophthalmologists with tools for personalized, preventative eye care. Its business model is built on direct sales of test kits and establishing partnerships within eye care networks.

Ophthalmology

Technology Platform

Integrated genetic and health factor analysis platform for polygenic risk scoring (PRS) in Age-Related Macular Degeneration (AMD). Utilizes DNA from a cheek swab combined with patient health data to generate personalized risk assessments.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The large and growing aging population with AMD presents a substantial addressable market.
There is a significant trend towards personalized and preventative medicine, which aligns perfectly with genetic risk testing.
Building a network of eye care practitioners as advocates can drive rapid clinical adoption and create a durable sales channel.

Risk Factors

The company's success is heavily reliant on convincing the eye care community of the clinical utility and value of genetic testing for AMD, which is not yet a standard of care.
Reimbursement from insurance payors is uncertain, potentially limiting patient access.
The business is concentrated on a single disease area, creating significant concentration risk.

Competitive Landscape

Visible Genomics competes with other companies offering genetic risk tests for AMD, such as ArcticDX (Macula Risk). It also faces competition from broader genetic testing companies that may expand into ophthalmology and from academic medical centers offering lab-developed tests. Its key differentiator is the integrated risk assessment combining genetics and health factors, and a focused commercial strategy on eye care providers.

More companies in Diagnostics & Precision Medicine →More companies in United States →